<- Go Home
Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Market Cap
$20.5B
Volume
4.3M
Cash and Equivalents
$618.7M
EBITDA
$1.6B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$2.7B
Profit Margin
112.44%
52 Week High
$49.06
52 Week Low
$30.96
Dividend
1.96%
Price / Book Value
3.17
Price / Earnings
26.89
Price / Tangible Book Value
3.70
Enterprise Value
$32.1B
Enterprise Value / EBITDA
20.15
Operating Income
$1.6B
Return on Equity
13.20%
Return on Assets
5.15
Cash and Short Term Investments
$637.5M
Debt
$9.0B
Equity
$9.7B
Revenue
$2.4B
Unlevered FCF
-$500.6M
Sector
Pharmaceuticals
Category
N/A